| P2093 | author name string | Alfredo Chetta | |
| | Andrea Zanini | |
| | Dario Olivieri | |
| P2860 | cites work | Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. | Q22008760 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Angiogenesis in health and disease | Q29614541 |
| | Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary | Q29614692 |
| | The nature of small-airway obstruction in chronic obstructive pulmonary disease | Q29618682 |
| | Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis | Q30489396 |
| | Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing | Q33369875 |
| | FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer | Q34004891 |
| | Cellular and structural bases of chronic obstructive pulmonary disease | Q34260279 |
| | Vasculogenesis | Q34387300 |
| | Management of chronic obstructive pulmonary disease | Q34548842 |
| | Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs | Q34653531 |
| | Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects | Q34792580 |
| | Airway vascular remodeling in asthma | Q35058272 |
| | Neovastat--a novel antiangiogenic drug for cancer therapy | Q35060415 |
| | Vascularity in asthmatic airways: relation to inhaled steroid dose | Q35533103 |
| | Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease | Q35537429 |
| | Airway microvascular extravasation and luminal entry of plasma | Q35583611 |
| | Prospects for new drugs for chronic obstructive pulmonary disease | Q35885857 |
| | Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD). | Q36130411 |
| | Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma | Q36357986 |
| | Kinase inhibitors and airway inflammation. | Q36392316 |
| | Transcription factors in airway diseases | Q36545751 |
| | Vascular remodelling and angiogenesis in asthma: morphological aspects and pharmacological modulation | Q36757675 |
| | Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy | Q36779299 |
| | Vascular endothelial growth factor trap in non small cell lung cancer | Q36899899 |
| | Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead | Q37031727 |
| | Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1. | Q39710943 |
| | Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction | Q40251249 |
| | Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis | Q40377374 |
| | New perspectives on basic mechanisms in lung disease. 4. Why are the airways so vascular? | Q40909525 |
| | Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma | Q43650596 |
| | Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma | Q43660405 |
| | Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone | Q44240285 |
| | Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial | Q44313160 |
| | Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma | Q44803823 |
| | Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells | Q46738605 |
| | The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). | Q47401096 |
| | Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer | Q47580940 |
| | Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. | Q47880688 |
| | Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. | Q47887404 |
| | Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease | Q51676143 |
| | Increased Airway Vascularity in Newly Diagnosed Asthma Using a High-magnification Bronchovideoscope | Q51819888 |
| | Small airway dimensions in smokers with obstruction to airflow. | Q54315890 |
| | Repression of Inflammatory Gene Expression in Human Pulmonary Epithelial Cells by Small-Molecule I B Kinase Inhibitors | Q58450575 |
| | Increased activation of p38 MAPK in COPD | Q58877117 |
| P433 | issue | 3 | |
| P921 | main subject | microvasculature remodeling | Q6840464 |
| P304 | page(s) | 179-187 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Therapeutic advances in respiratory disease | Q26842252 |
| P1476 | title | Therapeutic perspectives in bronchial vascular remodeling in COPD. | |
| P478 | volume | 2 | |